Authors
Latest:
Challenges in the Management of Mycobacterium abscessus ComplexThis pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.
Latest:
Supporting Patients With HIVAdvice to community physicians regarding ways to enhance patient-provider relationships and navigate barriers that impact the management of HIV infections.
Latest:
Correcting the Lack of Diversity in Clinical Trials With Community-Based StudiesAmmara Mushtaq, MD, discusses the underrepresentation of different races during the pandemic, but also the newer efforts to include and represent these communities in smaller, local studies.
Latest:
Updates in the Treatment of Mycobacterium TuberculosisThe latest Bench to Bedside column reviews new guidance on the treatment of drug-susceptible and drug-resistance Mycobacterium tuberculosis infections.
Latest:
Reduced-Dose Trimethoprim-Sulfamethoxazole Effective in Treating Mild to Moderate Pneumocystis jirovecii PneumoniaHere is a review of using this therapy in this patient population.
Latest:
In These COVID 19 Times, Can We Reduce Hospitalizations Due to Skin Infections?Shortages of health care workers and an increase in COVID-19 cases has put a severe strain on the health care system. Thus, the opportunity to reduce the hospitalizations for other conditions and expand outpatient treatment opportunities should be welcomed.
Latest:
Reducing Peripheral Venous Catheter InfectionsLack of data may mean bloodstream infections caused by PVCs are an overlooked cause of morbidity in hospitalized patients.
Latest:
Kalihinol Analog Targets Apicoplast Function In Malaria TreatmentKarine G. Le Roch, PhD, discussed her research on a kalihinol analog that combats drug resistance in malaria, emphasizing the need for innovative treatments in the context of climate change and rising transmission rates.
Latest:
Final Diagnosis: Pott Puffy Tumor With Subdural EmpyemaA rare case of Pott puffy tumor occurs in an atypical patient with no risk factors, likely due to untreated sinus infection.
Latest:
Evaluating Safety and Efficacy of Vaxart's Oral Vaccine's Impact on COVID-19 VariantsPart 2 with James F Cummings, MD, as he discusses the need for a stronger response to emerging variants, the importance of protecting high-risk populations, and the potential to reduce vaccine hesitancy through easier administration.
Latest:
“Triple Therapy” Facing Triple ThreatClinicians provide an overview of intraamniotic infections and offer treatment strategies for these challenging infections.
Latest:
The Underlying Threat of Multidrug-Resistant Pathogens in the COVID-19 EraOver half of patients admitted with positive SARS-CoV-2 testing received antibiotics, but evidence of bacterial infection is uncovered in far fewer cases. We may already be seeing the effects of antibiotic overprescribing.
Latest:
Biden Administration Unveils HCV Initiative: A Significant Step Towards Public HealthThe federal government is working to provide greater access to testing and treatment.
Latest:
Shifting to Shorter Courses of Antibiotic Therapy for Common Pediatric InfectionsIn the latest SIDP column, two clinicians provide information on recent studies and guidelines directed at antibiotic durations in this patient population.
Latest:
Investigational Hepatitis D Therapy Well-Tolerated, Safe for Chronic Disease at Week 48In a study evaluating bulevirtide as monotherapy, investigators found the antiviral to be safe and tolerable following nearly a year of treatment.
Latest:
Sepsis Awareness Month: Highlighting the Findings from BLINGIIIContinuous antibiotic infusions show positive results and may improve outcomes for patients with severe sepsis.
Latest:
Differentiating Between DNA and mRNA PlatformsAmi Patel, PhD, provides insights on both technologies and how her research center, the Wistar Institute, is involved in DNA vaccine and monoclonal antibody research.
Latest:
Sticking It to COVID-19: The Expansion of the Pfizer-BioNTech Vaccine EUAA review of the data and circumstances that led to authorization in children ages 5 to 11 years.
Latest:
So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.
Latest:
Final Diagnosis: Donor-Derived Staphylococcus Iugdunensis Endocarditis of Transplanted Heart"This case gives uncomfortable insight into a gap in early detection of infections in immunocompromised, high-risk patient populations. "
Latest:
Injection Drug Use and Immunodeficiency Linked to Failed Hepatitis C Treatment in People with HIVLower CD4+ cell counts, HCV genotype 4, and recent injection drug use were linked to unsuccessful DAA treatment in people with HCV and HIV.
Latest:
Preparing for the Next Long-acting AntiretroviralsClinicians can make room for infrequent treatment options as patients enjoy their daily lives.
Latest:
The Business Sector's Advocacy to Maintain Funding for HIV Prevention, Research, TreatmentA coalition of employers, the US Business Action to End HIV, sent a letter to Congress outlining the continued need for support from the federal government.
Latest:
Gilead and Merck Report Successful Phase 2 Results for Investigational Once-Weekly HIV TreatmentThe combination of the antiviral agents islatravir and lenacapavir demonstrates both efficacy and safety, leading to advancement into Phase 3 trials.
Latest:
Tips for Talking with Patients about Fecal Microbiota Transplant for Recurrent C. difficile InfectionsTo close the discussion, experts on C. difficile infections discuss how they talk with patients about fecal microbiota transplantation.
Latest:
Echinocandin Dosing Considerations in Obese Patients: A ReviewObesity significantly impacts the pharmacokinetics (PK) of antifungal drugs like echinocandins, including volume of distribution (Vd) and clearance. However, despite these PK differences, current clinical evidence generally does not support the need for universal dose adjustments in obese patients. Clinicians should consider personalized dosing based on patient characteristics, infection severity, and specific drug properties due to echinocandins' favorable safety profiles.
Latest:
COVID-19 Impact on Antimicrobial Stewardship: Consequences and Silver LiningsThis crisis has united multidisciplinary groups and laid the foundation to better equip the health care workforce for future pandemics.
